Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formul...
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
- Conditions
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00462982
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00459979
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00459875
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
- Conditions
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 960
- Registration Number
- NCT00457392
- Locations
- 🇬🇧
Pfizer Investigational Site, Yeovil, Somerset, United Kingdom
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 768
- Registration Number
- NCT00457691
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Sunitinib in Refractory Adrenocortical Carcinoma
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- University of Wuerzburg
- Target Recruit Count
- 39
- Registration Number
- NCT00453895
- Locations
- 🇩🇪
Charite Berlin, Berlin, Germany
🇩🇪Dept. of Medicine I, University of Wuerzburg, Wuerzburg, Germany
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
- Conditions
- Interventions
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00453310
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 156
- Registration Number
- NCT00453154
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Heartland Cancer Research NCORP, Decatur, Illinois, United States
🇺🇸Illinois CancerCare-Princeton, Princeton, Illinois, United States
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT00451048
- Locations
- 🇨🇦
Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 520
- Registration Number
- NCT00444795
- Locations
- 🇰🇷
Hwasun Hospital, Chonnam National University, Cheonnam, Korea, Republic of
🇰🇷Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷Chosun University Hospital, Gwang Joo, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.